701![Hyperium SUMMARY OF PRODUCT CHARATERISTICS HYPERIUM I.N.N. : Rilmenidine Hyperium SUMMARY OF PRODUCT CHARATERISTICS HYPERIUM I.N.N. : Rilmenidine](https://www.pdfsearch.io/img/fb5e04d9ec02e74778ea022791a3ec8a.jpg) | Add to Reading ListSource URL: www.servier.comLanguage: English - Date: 2014-01-29 08:20:31
|
---|
702![Assessing Stroke Risk in Patients With AF │Janssen Pharmaceuticals, Inc. Assessing Stroke Risk in Patients With AF │Janssen Pharmaceuticals, Inc.](https://www.pdfsearch.io/img/e68bb5be311976de0332f58e07274a98.jpg) | Add to Reading ListSource URL: www.janssenpharmaceuticalsinc.comLanguage: English - Date: 2013-08-19 12:47:46
|
---|
703![1 STATE OF MA DOCUMENTATION PROJECT COMPLICANCE REVIEW TEAM[removed]Consultant: Mary Thornton, MTA, Inc. Facilitator: Kathy Janssen, Riverside 1 STATE OF MA DOCUMENTATION PROJECT COMPLICANCE REVIEW TEAM[removed]Consultant: Mary Thornton, MTA, Inc. Facilitator: Kathy Janssen, Riverside](https://www.pdfsearch.io/img/2db91652dd89b82b7f300614d01a450a.jpg) | Add to Reading ListSource URL: www.mhsacm.orgLanguage: English - Date: 2010-01-27 10:54:19
|
---|
704![Microsoft Word - TOPAMAX - WordDoc 30_07_2014 Microsoft Word - TOPAMAX - WordDoc 30_07_2014](https://www.pdfsearch.io/img/31315d21984a59ed8941ede2391d44cb.jpg) | Add to Reading ListSource URL: www.medsafe.govt.nzLanguage: English - Date: 2014-08-18 00:05:04
|
---|
705![Prescribing Treatment Is Only the First Step— Patient Adherence Drives Outcomes Janssen Pharmaceuticals, Inc. Prescribing Treatment Is Only the First Step— Patient Adherence Drives Outcomes Janssen Pharmaceuticals, Inc.](https://www.pdfsearch.io/img/6d7ba57c0726a9729fb55867f9d43657.jpg) | Add to Reading ListSource URL: www.janssenpharmaceuticalsinc.comLanguage: English - Date: 2013-08-21 11:13:10
|
---|
706![Influence of positive allosteric modulation of the mGlu2-receptor on the behavioral responses in animal models of depression Neuroscience Discovery Janssen Research and Development, a Division of Janssen Pharmaceutica NV Influence of positive allosteric modulation of the mGlu2-receptor on the behavioral responses in animal models of depression Neuroscience Discovery Janssen Research and Development, a Division of Janssen Pharmaceutica NV](https://www.pdfsearch.io/img/b1706fbf941e844cfd82f3b28a94e348.jpg) | Add to Reading ListSource URL: www.adaa.orgLanguage: English - Date: 2014-06-04 13:03:20
|
---|
707![Microsoft Word - MODECATE_E_PM_ 08 March 2013_APP_CLN.DOC Microsoft Word - MODECATE_E_PM_ 08 March 2013_APP_CLN.DOC](https://www.pdfsearch.io/img/3e1f48f7586a78c2b96e25032233cceb.jpg) | Add to Reading ListSource URL: www.bmscanada.caLanguage: English - Date: 2013-03-21 09:49:03
|
---|
708![U11 Boys Rosters First Name Last Name Team U11 Boys Rosters First Name Last Name Team](https://www.pdfsearch.io/img/da06fe5a58e0086a5a80f580cdca57d1.jpg) | Add to Reading ListSource URL: media1.razorplanet.comLanguage: English - Date: 2014-03-11 21:41:17
|
---|
709![Complexities of Warfarin Therapy May Lead to Increased Resource Utilization Janssen Pharmaceuticals, Inc.
Managing the Burden of Complexities of Warfarin Therapy May Lead to Increased Resource Utilization Janssen Pharmaceuticals, Inc.
Managing the Burden of](https://www.pdfsearch.io/img/0123dda1c4b31464b69b38f84aa17708.jpg) | Add to Reading ListSource URL: www.janssenpharmaceuticalsinc.comLanguage: English - Date: 2013-08-21 11:12:18
|
---|
710![SPORANOX® (itraconazole) Oral Solution Congestive Heart Failure: When itraconazole was administered intravenously to dogs and healthy human volunteers, negative inotropic effects were seen. If signs or symptoms of conge SPORANOX® (itraconazole) Oral Solution Congestive Heart Failure: When itraconazole was administered intravenously to dogs and healthy human volunteers, negative inotropic effects were seen. If signs or symptoms of conge](https://www.pdfsearch.io/img/59df43087a0d3479b47192a273ef6fb2.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2009-03-31 14:50:55
|
---|